Navigation Links
Depression not discussed during rheumatoid arthritis doctor visits
Date:2/1/2008

Patients with rheumatoid arthritis (RA), the most common chronic inflammatory arthritis, are twice as likely as other individuals to experience depression. Although depression in primary care has been well studied, no studies have examined whether rheumatologists and RA patients discuss depression during medical visits. A new study published in the February issue of Arthritis Care & Research (http://www.interscience.wiley.com/journal/arthritiscare) found that patients whose activities were more restricted due to their arthritis were more than twice as likely to have moderately severe to severe symptoms of depression. It also found that few depressed patients discussed their condition with their rheumatologists and the subject was always brought up by the patients as opposed to the physicians.

Led by Betsy Sleath, of the University of North Carolina at Chapel Hill, NC, the study included 200 RA patients from four rheumatology clinics with eight participating doctors. Patient visits were audiotaped and patients were interviewed after their medical visits using a questionnaire to measure their mental status.

The results showed that almost 11% of the patients in the study had moderately severe to severe symptoms of depression and that those who were rated as being more restricted in their normal activities were significantly more likely to have these symptoms. Furthermore, only 1 in 5 of the patients who showed symptoms discussed depression with their rheumatologists and they were always the ones to bring up the topic. Even when depression was brought up, it was often not discussed at any length.

When patients visit their rheumatologists, their main focus is their RA, yet such chronic diseases can greatly impact a patients psychosocial well-being. In addition, many RA patients see their rheumatologists more often then their primary care physician and depression can also affect a patients adherence to treatment regimens. For these reasons the authors suggest that it is important for rheumatologists to consider addressing both the RA and the depression when they see their patients. The authors note that some physicians may not feel comfortable discussing depression with their patients, but they should consider having their office staff administer a brief depression screening before the patients visits in order to identify problems early on.

In addition to screening for depression, the authors suggest it is important for patients to have access to appropriate treatment. Rheumatologists can treat the depression themselves, refer patients to a mental health professional, or communicate with the patients primary care physician to coordinate a treatment plan. Also, given how common depression is in these patients, rheumatology training programs should educate physicians about the importance of screening for and treating depression.

Failure to detect and treat depression may compromise patients adherence to regimens and, ultimately, their health outcomes, the authors conclude. Future research should examine patient- and physician-reported barriers to communicating about depression in rheumatology practices and use these findings to design innovative interventions that can be delivered effectively in busy rheumatologist practices.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Blue Cross of California Launches Maternity Depression Program
2. Depression and anxiety can double chances of heart ailments
3. Depression, Obesity Coexist in Many Middle-Aged Women
4. Walk away menopausal anxiety, stress and depression
5. Realistic Expectations Help Ward Off Holiday Depression
6. Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
7. Treating Depression Cuts Diabetes Death Risk
8. Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression
9. Lack of Light and Seasonal Depression - Whats the Link? From the Harvard Health Letter
10. Venlafaxine extended-release effective for patients with major depression
11. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: